论文部分内容阅读
目的探讨赫赛汀联合多西他赛在局部浸润性乳腺癌治疗中的疗效。方法将在2012年1月~2014年12月期间进入我院肿瘤科治疗的120例局部浸润性乳腺癌患者纳入课题研究,随机分为常规治疗组和研究组,各60例患者,常规治疗组采用多柔比星+环磷酰胺治疗,研究组在对照组基础上加用赫赛汀联合多西他赛治疗,共治疗8个疗程。观察治疗后乳腺癌组织标本的HMGI~C基因表达和血清C反应蛋白水平,评价两组疗效。结果与常规治疗组相比,研究组降低了HMGI-C阳性率(P<0.05);加用赫赛汀联合多西他赛后,升高了研究组的平均LI值、HER2阳性率、p53阳性率、雌激素受体阴性率(P<0.05);同时,降低了研究组血清CRP水平(P<0.05)。结论赫赛汀联合多西他赛能够提高局部浸润性乳腺癌的治疗效果,使患者HMGI-C和CRP的表达水平降低,进而使患者预后得到改善。
Objective To investigate the efficacy of Herceptin combined with docetaxel in the treatment of locally invasive breast cancer. Methods A total of 120 patients with locally invasive breast cancer admitted to the Department of Oncology in our hospital from January 2012 to December 2014 were enrolled in the study. They were randomly divided into the conventional treatment group and the study group, with 60 patients in each group. The conventional treatment group Adopt doxorubicin + cyclophosphamide treatment, the study group in the control group plus Herceptin combined docetaxel treatment, a total of 8 courses of treatment. The HMGI ~ C gene expression and serum C-reactive protein level in the breast cancer tissue specimens were observed to evaluate the curative effect of the two groups. Results Compared with the conventional treatment group, the study group decreased the positive rate of HMGI-C (P <0.05). After adding Herceptin combined with docetaxel, the mean LI value, HER2 positive rate, p53 Positive rate and estrogen receptor negative rate (P <0.05). At the same time, the level of CRP in study group decreased (P <0.05). Conclusions Herceptin combined with docetaxel can improve the therapeutic effect of locally invasive breast cancer and lower the expression of HMGI-C and CRP in patients, thus improving the prognosis of patients.